Adding an oncolytic virus to classic immune checkpoint inhibition elicits treatment responses and survival benefit for select immunologically ‘cold’ recurrent glioblastomas, although creative treatment strategies are still needed for patients with highly anti-inflammatory tumors.
References
Reardon, D. A. et al. JAMA Oncol. 6, 1003–1010 (2020).
Lim, M. et al. Neuro Oncol. 24, 1935–1949 (2022).
Omuro, A. et al. Neuro Oncol. 25, 123–134 (2023).
Nassiri, F. et al. Nat. Med. https://doi.org/10.1038/s41591-02347-y (2023).
Moehler, M. H. et al. Hum. Gene Ther. 16, 996–1005 (2005).
Lang, F. F. et al. J. Clin. Oncol. 36, 1419–1427 (2018).
Ribas, A. et al. Cell 170, 1109–1119 (2017).
Lu, Y. et al. Nat. Commun. 12, 4031 (2021).
Vogelbaum, M. A. et al. Neuro Oncol. 22, 1568–1579 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.L. receives research support from Arbor, BMS, Accuray, Biohaven and Urogen; is a research consultant for VBI, InCephalo Therapeutics, Merck, Pyramid Bio, Insightec, Biohaven, Sanianoia, Hemispherian, Novocure, Noxxon, InCando, Century Therapeutics, CraniUs, MediFlix and XSense; is a shareholder of Egret Therapeutics; has patents for focused radiation plus checkpoint inhibitors, local chemotherapy plus checkpoint inhibitors, and checkpoints for neuro-inflammation; is a non-research consultant for Stryker; and is on the Data Safety and Monitoring Board for Cellularity.
Rights and permissions
About this article
Cite this article
Wu, A., Lim, M. Advancing combination therapy for recurrent glioblastoma. Nat Med 29, 1318–1319 (2023). https://doi.org/10.1038/s41591-023-02350-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02350-3
- Springer Nature America, Inc.